Gain Therapeutics to Participate in the Oppenheimer 33rd Annual Healthcare Conference

Rhea-AI Summary

Gain Therapeutics, Inc. (Nasdaq: GANX) announced that its CEO, Matthias Alder, will present at the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023, at 8:40 AM ET. The conference will be conducted online, and a live webcast of the presentation can be accessed through the Company’s website. Gain Therapeutics specializes in drug discovery using a proprietary computational platform to identify novel allosteric binding sites for small molecule treatments. Their pipeline includes programs targeting neurodegenerative diseases and other disorders. The company has received funding support from various foundations and programs for its lead program in Parkinson’s disease.

BETHESDA, Md., March 09, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced that Matthias Alder, Chief Executive Officer, will present at the Oppenheimer 33^rd Annual Healthcare Conference, taking place March 14-16 online. Please see additional details below:

Oppenheimer 33^rd Annual Healthcare Conference
Date: Tuesday, March 14, 2023
Time: 8:40AM ET
Format: Corporate Presentation
Webcast: Registration link

A live webcast of the presentation can be accessed through the Events section of the Company’s website at https://www.gaintherapeutics.com/investors-media/overview.html. An archived replay of the webcast will be available on the Company’s website for 90 days following the live presentation.

About Gain Therapeutics, Inc.

Gain Therapeutics, Inc. is transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments to address unmet medical needs. The ability to identify never-seen-before allosteric targets on proteins involved in diseases across the full spectrum of therapeutic areas provides opportunities for a range of drug-protein interactions, including protein stabilization, protein destabilization, targeted protein degradation, allosteric inhibition, and allosteric activation. Gain’s pipeline spans neurodegenerative diseases, lysosomal storage disorders (LSDs), metabolic disorders, as well as other diseases that can be targeted through protein degradation, such as oncology. Gain’s lead program in Parkinson’s disease has been awarded funding support from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The Silverstein Foundation for Parkinson’s with GBA, as well as from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and Innosuisse. For more information, please visit https://www.gaintherapeutics.com.

Investor & Media Contact:
Argot Partners
(212) 600-1902
Gain@argotpartners.com

FAQ

When will Gain Therapeutics present at the Oppenheimer 33rd Annual Healthcare Conference?

Gain Therapeutics will present on March 14, 2023, at 8:40 AM ET.

Where can I watch the Gain Therapeutics presentation from the Oppenheimer Conference?

The presentation can be viewed live through the Events section of Gain Therapeutics' website.

What is Gain Therapeutics known for?

Gain Therapeutics is known for transforming drug discovery using a proprietary computational platform that identifies novel allosteric binding sites.

What diseases does Gain Therapeutics' pipeline target?

Gain Therapeutics' pipeline targets neurodegenerative diseases, lysosomal storage disorders, metabolic disorders, and oncology.

Has Gain Therapeutics received funding for its Parkinson's disease program?

Yes, Gain Therapeutics has received funding support from The Michael J. Fox Foundation and other organizations for its Parkinson's disease program.